JBiChem

J-Biochem is a clinical-stage biotechnology company based in Suzhou, China, dedicated to developing next-generation peptide therapeutics for metabolic disorders. The company specializes in multi-receptor agonists, particularly dual and triple agonists targeting the GLP-1, GIP, and glucagon receptors. Its lead program, JBC-01, is a long-acting triple agonist currently in Phase 2 clinical trials for the treatment of obesity and type 2 diabetes. J-Biochem leverages its proprietary peptide engineering platform to design molecules with optimized pharmacokinetic profiles and enhanced efficacy. Founded by industry veterans from Merck & Co., the company aims to address the growing global burden of chronic metabolic diseases through innovative biologics.